Early-Stage blood cancer vaccine trial tests new drug combo
NCT ID NCT02886065
Summary
This early-stage study is testing the safety of a new cancer vaccine (PVX-410) combined with other drugs for people with smoldering multiple myeloma, an early form of blood cancer. The goal is to see if these combinations can safely boost the immune system to fight the cancer cells. The study involves 19 participants and is primarily focused on determining safe doses and checking for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMOLDERING MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02115, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
University Hospital of Cleveland- Seidman Cancer Center
Cleveland, Ohio, 44106, United States
-
Weill Cornell Medical College
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.